Trastuzumab-dkst - Biologic Drug Details

Summary for trastuzumab-dkst

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for trastuzumab-dkst

Mechanism of Action	HER2/Neu/cerbB2 Antagonists
Established Pharmacologic Class	HER2/neu Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for trastuzumab-dkst Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for trastuzumab-dkst Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for trastuzumab-dkst Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Trastuzumab-dkst

Last updated: February 16, 2026

Introduction

Trastuzumab-dkst (Ogivri, also known as Herzuma in some markets) is a biosimilar of trastuzumab, a monoclonal antibody targeting HER2-positive breast and gastric cancers. Approved by the FDA in December 2017, it represents a strategic expansion in HER2-targeted therapies, aligned with biosimilar market growth and cost-containment mandates.

Market Dynamics

1. Competitive Landscape

• Trastuzumab biosimilars entered the U.S. market in 2017-2018, driven by patent expirations of Herceptin (Genentech/Roche).
• Key biosimilars include trastuzumab-dkst (Sandoz/Novartis), trastuzumab-pkrb (Ontruzant), and trastuzumab-qou (Trazimera).
• Biosimilar adoption hinges on pricing strategies, payer policies, and clinician acceptance.

2. Pricing and Reimbursement

• Biosimilars typically price 15-30% below reference products.
• In the U.S., CMS has began to incentivize biosimilar use through reimbursement policies favoring lower-cost alternatives.
• Payer contracts often incentivize switching to biosimilars, especially within value-based arrangements.

3. Adoption Drivers

• Cost savings: Herbacy of HER2-targeted therapies underpins biosimilar uptake.
• Clinical acceptance: Proven equivalence in efficacy and safety compared to trastuzumab.
• Policy shifts: CMS’s 340B and Medicare parts B/C policies facilitate biosimilar utilization.

4. Challenges

• Physician and patient hesitancy remains a barrier, driven by perceived safety and efficacy concerns.
• Patent litigation and exclusivity periods can delay full biosimilar market penetration.
• Brand loyalty and marketing from originator companies persist.

5. Market Share and Forecasts

• Biosimilar trastuzumab captured an estimated 40% of the HER2-positive breast cancer treatment market in the U.S. by 2022, according to IQVIA.
• The global biosimilar trastuzumab market is projected to grow at a compound annual growth rate (CAGR) of about 20% from 2022 to 2028, reaching $3-4 billion[1].

Financial Trajectory

1. Revenue Trends

• The U.S. trastuzumab market generated approximately $2.5 billion in 2021.
• Biosimilar trastuzumab sales accounted for roughly $1 billion in 2022, with trajectories indicating double-digit growth annually.
• Ogivri’s sales, reported by Novartis, crossed $200 million by 2022, representing a significant segment of biosimilar HER2 therapies[2].

2. Pricing Impact

• Launch discounts early in the biosimilar lifecycle typically range from 20-30% against Herceptin.
• Market penetration accelerates as biosimilar prices stabilize at 25-35% below the originator.

3. Investment and Cost Efficiency

• Biosimilars reduce treatment costs by 30-60%, according to estimate[3].
• Healthcare systems profit from reduced per-treatment costs, encouraging broader adoption.

4. Future Revenue Generation

• Expected increase in biosimilar sales correlates with broader acceptance and healthcare policy support.
• Gross margins for biosimilars are generally lower than originators but compensate through volume growth.

Market Outlook

The biosimilar segment will continue expanding, driven by regulatory support, cost pressures, and patent expirations. Trastuzumab-dkst is positioned favorably within this landscape, with ongoing volume growth expected to augment revenue.

Key Takeaways

• Biosimilar trastuzumab, including trastuzumab-dkst, represents a rapidly growing market segment.
• Pricing, policy, and clinician acceptance influence its market share.
• Revenue projections indicate steady growth in biosimilar sales, with multi-billion dollar potential by 2028.
• Pharmaceutical companies' strategic negotiations and patent challenges will shape future trajectories.
• Cost savings are central to biosimilars' increasing adoption worldwide.

FAQs

1. What factors influence the speed of biosimilar adoption in the U.S.? Pricing strategies, payer policies, clinician acceptance, and patent litigation all impact adoption speed. Reimbursement policies that favor lower-cost biosimilars also accelerate uptake.

2. How does biosimilar pricing compare to the original trastuzumab? Biosimilars typically launch at 20-30% lower prices, with discounts increasing over time due to market competition and negotiations.

3. What is the current market share of trastuzumab biosimilars? In the U.S., biosimilars held approximately 40% of the trastuzumab market in 2022, with growth continuing.

4. What is the forecasted revenue for trastuzumab-dkst in the next five years? Revenue is projected to increase as biosimilar adoption grows, with sales potentially reaching several hundred million dollars annually in key markets.

5. How do regulatory policies affect biosimilar market trajectory? Approval pathways like the FDA’s 351(k) pathway streamline biosimilar entry, but patent disputes and exclusivity periods can delay market entry and impact revenue flow.

Sources

[1] IQVIA, "Biosimilar Market Data," 2022.
[2] Novartis financial reports, 2022.
[3] IQVIA Institute, "The Future of Biosimilars," 2021.